

CV Date	21/04/2025
----------------	------------

Part A. PERSONAL INFORMATION

First Name *	Santiago		
Family Name *	Cabezas Camarero		
Sex *	Male	Date of Birth *	20/10/1981
ID number Social Security, Passport *	44837145W	Phone Number *	(+34) 913303000
URL Web			
Email Address	santicc81@gmail.com		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *		
	Researcher ID		
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Especialista en Oncología Médica		
Starting date	2015		
Institution	Hospital Clínico Universitario San Carlos		
Department / Centre			
Country		Phone Number	
Keywords	Clinical medicine		

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2010 - 2015	Resident in Medical Oncology / Hospital Clínico San Carlos

A.3. Education

Degree/Master/PhD	University / Country	Year
Master en Oncología Neurológica	Universidad San Pablo CEU	2021
Doctor en Medicina	Universidad Complutense de Madrid	2021
Titulo propio de Inmuno-Oncología	Universidad de Navarra	2020
Licenciado en Medicina y Cirugía	Universidad de Santiago de Compostela	2005
Licenciado en Medicina y Cirugía	Universidad Claude Bernard, Lyon 1, Francia	2005

Part B. CV SUMMARY

Santiago Cabezas Camarero is a consultant in Medical Oncology since 2015. He works in the Medical Oncology Department of Hospital Clinico Universitario San Carlos in Madrid, with special dedication to the treatment of Head and Neck Cancer, Central Nervous System Tumors and Familial Cancer. In 2021 he earned his PhD in Medicine from Universidad Complutense de Madrid, with a project on Circulating Tumor Cells in patients with Colorectal Cancer and Head and Neck Cancer. In 2021 he graduated with the "Expert Title in Immuno-Oncology" from Universidad de Navarra in Madrid. Also in 2021, he obtained his Master Degree in Neuro-Oncology from Universidad San Pablo CEU in Madrid. He is currently participating as principal investigator and sub-investigator in several clinical trials with different anti-tumor therapies, particularly with immune checkpoint inhibitors. He is the principal investigator of several translational research projects of biomarkers and liquid biopsy in head and neck cancer, brain tumors and has published more 35 articles in PUBMED-indexed scientific journals.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Santiago Cabezas Camarero; Rebeca Pérez Alfayate; Vanesa García Barberán; et al; Pedro Pérez Segura. 2025. ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma. *Annals of Oncology*. Elsevier. S0923-7534-25, pp.00064-00064.
- 2 **Scientific paper.** Rebeca Pérez Alfayate; Santiago Cabezas Camarero; Juan Pablo Castaño Montoya; Ana Alejandra Arévalo Sáenz; Ángela Carrascosa Granada; Pedro Alonso Lera; Giovanni Grasso. 2025. Communicating hydrocephalus in glioblastoma presenting as chronic hydrocephalus: systematic review and meta-analysis. *Acta Neurochir (Wien)*. SpringerLink. 167-1, pp.19-19.
- 3 **Scientific paper.** Santiago Cabezas Camarero; María Nieves Cabrera Martín; María Cruz Iglesias Moreno; Pedro Pérez Segura. 2024. Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer. *Anticancer Drugs*. Lippincott. 35-9, pp.875-877.
- 4 **Scientific paper.** Miguel Alonso Juarranz; Oscar de la Sen; Pablo Pérez; et al; Farzin Falahat. 2024. Exceptional Evolution of a Squamous Odontogenic Tumor in the Jaw: Molecular Approach. *International Journal of Molecular Sciences*. MDPI. 25-17, pp.9547-9547.
- 5 **Scientific paper.** Santiago Cabezas Camarero; Rebeca Pérez Alfayate; Carmen Polidura; María Natividad Gómez Ruiz; Lidia Gil Martínez; Isabel Casado Fariñas; Jorge Bartolomé; Pedro Pérez Segura. 2024. Durable benefit and slowdown in tumor growth dynamics with erdafitinib in a FGFR3-TACC3 fusion-positive IDH-wild type glioblastoma. *Neurooncology Advances*. Oxford University Press. 6-1, pp.vdae139-vdae139.
- 6 **Scientific paper.** Santiago Cabezas Camarero; Pedro Pérez Segura; Alejandro Riquelme; Javier Román García. 2024. Profound ctDNA and radiological responses after 2 cycles of avelumab in a metastatic Merkel cell carcinoma of the head and neck. *Oral Oncology*. Elsevier. 157-106971, pp.1-4.
- 7 **Scientific paper.** Santiago Cabezas Camarero; María Cruz Iglesias Moreno; Elena Cerezo Druet; Miguel J Sotelo; Salomé Merino Menéndez; María Nieves Cabrera Martín; José Carlos Plaza Hernández; Pedro Pérez Segura. 2024. Response to Yilmaz et al. *Anticancer Drugs*. Lippincott. 35-5, pp.481-482.
- 8 **Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barberán; Rebeca Pérez Alfayate; María Elena Gómez del Pulgar; María Nieves Cabrera Martín; Isabel Casado Fariñas; Pedro Pérez Segura. 2024. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib. *The Oncologist*. Oxford Academic. 29-5, pp.377-383.
- 9 **Scientific paper.** Santiago Cabezas Camarero; Gonzalo Vázquez Masedo; Fernando Puebla Díaz; Juan Antonio Corona; Pedro Pérez Segura. 2024. Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer. *Oral Oncology*. Elsevier. 150-106719, pp.1-4.
- 10 **Scientific paper.** Santiago Cabezas Camarero; María Cruz Iglesias Moreno; Elena Cerezo Druet; Miguel J Sotelo; Salomé Merino Menéndez; María Nieves Cabrera Martín; José Carlos Plaza Hernández; Pedro Pérez Segura. 2023. Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer. *Anticancer Drugs*. Lippincott. 34-5, pp.695-698.
- 11 **Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barberán; Javier David Benítez Fuentes. 2023. Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck. *Cancers (Basel)*. MDPI. 15-9, pp.2431.

- 12 Scientific paper.** Santiago Cabezas Camarero; Salomé Merino Menéndez; María Nieves Cabrera Martín; Miguel J. Sotelo; José Carlos Plaza Hernández; Farzin Falahat; María Cruz Iglesias Moreno; Pedro Pérez Segura. 2022. Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. *Oncology Letters*. Spandidos. 25-1, pp.37.
- 13 Scientific paper.** Santiago Cabezas Camarero; Rebeca Pérez Alfayate; Miguel J. Sotelo. 2022. Glioblastoma: an organ-confined disease?. *TCR Translational Cancer Research*. AME. 11-8, pp.2473-2476.
- 14 Scientific paper.** Santiago Cabezas Camarero; Juan A. Marín Jiménez; Marc Oliva; et al; Pedro Pérez Segura. 2022. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy. *Frontiers in Oncology*. Frontiers. 12-953020.
- 15 Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barberán; Rebeca Pérez Alfayate; Isabel Casado Fariñas; Hillary Sloane; Frederick S. Jones; Pedro Pérez Segura. 2022. Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas. *Cancers (Basel)*. MDPI. 14-12, pp.2891.
- 16 Scientific paper.** Santiago Cabezas Camarero; Pedro Pérez Segura. 2022. Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers. *Cancers (Basel)*. MDPI. 14-12, pp.2858.
- 17 Scientific paper.** Santiago Cabezas Camarero; Rebeca Pérez Alfayate; Vanesa García Barberán; et al; Pedro Pérez Segura. 2022. Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome-associated glioma. *Ther Adv Med Oncol*. SAGE. 14, pp.17588359221100863.
- 18 Scientific paper.** Santiago Cabezas Camarero; Pedro Pérez Segura. 2022. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective. *Crit Rev Oncol Hematol*. Elsevier. 169, pp.103569.
- 19 Scientific paper.** Rodrigo Motta; Santiago Cabezas Camarero; Cesar Torres Mattos; Alejandro Riquelme; Ana Calle; Paola Montenegro; Miguel J. Sotelo. 2021. Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives. *J Clin Transl Res*. 7-6, pp.771-785.
- 20 Scientific paper.** Cristina Saiz Ladera; Mariona Baliu Pique; Francisco J. Cimas; et al; Alberto Ocaña. 2021. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. *Front Oncol*. 11, pp.714550..
- 21 Scientific paper.** Stella Arambulo; Santiago Cabezas Camarero; Heinz Rojas; Miguel J. Sotelo. 2021. COVID-19 vaccination in cancer patients: Is it the time or should we wait?. *J Cancer Res Ther*. 17-6, pp.1.
- 22 Scientific paper.** Rodrigo Motta; Santiago Cabezas Camarero; César Torres Mattos; Alejandro Riquelme; Ana Calle; Alejandro Figueroa; Miguel J. Sotelo. 2021. Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives. *J Clin Transl Res*. 7-4, pp.511-522.
- 23 Scientific paper.** Santiago Cabezas Camarero; María Nieves Cabrera Martín; Salomé Merino Menéndez; et al; Pedro Pérez Segura. 2021. Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer. *The Oncologist*. Alfamedpress. 26-6, pp.e1018-e1035.
- 24 Scientific paper.** Santiago Cabezas Camarero; María Nieves Cabrera Martín; Melchor Sanz-Pardo Sanz; Pedro Pérez Segura. 2021. Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient. *Anticancer Drugs*. Wolters Kluwer Health, Inc. pp.1-5.
- 25 Scientific paper.** Miguel J Sotelo Lezama; Santiago Cabezas Camarero; Alejandro Riquelme; Coralía Bueno. 2020. Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy. *Journal of Cancer Research and Therapeutics*. Wolters Kluwer. 16-4, pp.941-945.

- 26 **Scientific paper.** EL Busch; VL Patel; B Buecher; Santiago Cabezas Camarero; Trinidad Caldés; TR Rebbeck. 2020. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. *Cancer Research*. 80-3, pp.624-638.
- 27 **Scientific paper.** Santiago Cabezas Camarero; Rebeca Pérez Alfayate; Fernando Puebla; María Nieves Cabrera Martín; Pedro Pérez Segura. 2019. Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer. *Oral Oncology*. Oral Oncol. 2019 Dec.
- 28 **Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barberán; Diana Hernanpérez Hidalgo; Melchor Saiz-Pardo Sanz; David de Pablo Velasco; Víctor Lorca; María Cruz Iglesias; Pedro Pérez Segura. 2019. Mutational profile of dysplastic lesions evolving to laryngeal cancer. *Journal of Clinical Oncology*. ASCO. 37, pp.e17551.
- 29 **Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barrerán; Virginia de la Orden García; et al; Eduardo Díaz-Rubio. 2019. RAS analysis of circulating tumor cells from advanced colorectal cancer using BEAMing technology. *Journal of Clinical Oncology*. ASCO. 37, pp.e15151.
- 30 **Scientific paper.** Santiago Cabezas Camarero; Virginia De la Orden García; Vanesa García Barrerán; Pedro Pérez Segura. 2019. Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy. *The Oncologist* 2019 Mar;24(3):293-300. *Alphamedpress*. 24-3, pp.293-300.
- 31 **Scientific paper.** Santiago Cabezas Camarero; Vanesa García Barrerán; Melchor Sáiz-Pardo Sanz; Pedro Pérez Segura. 2019. Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer. *Head Neck*. Wiley. doi: 10.1002/hed.256.
- 32 **Scientific paper.** ; ; Antonio Casado; et al; Eduardo Díaz-Rubio. 2019. Trabectedin for reversing platinum resistance and re sensitization to platinum in patients with recurrent ovarian cancer. *Future Oncol*. 2019 Jan;15(3):271-280. 15-3, pp.271-280.
- 33 **Scientific paper.** Santiago Cabezas Camarero; Pedro Pérez Segura. 2018. Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer. *Oral Oncol*. 2018 Dec;87:204-206. 87, pp.204-206.
- 34 **Scientific paper.** Santiago Cabezas Camarero; Pedro Pérez Segura. 2018. Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer. *Anticancer Drugs*. 2019 Feb;30(2):149-152. Wolter Kluvers. 30-2, pp.149-152.
- 35 **Scientific paper.** Santiago Cabezas Camarero; Virginia de la Orden García; Silvia Veganzones de Castro; et al; Eduardo Díaz-Rubio García. 2016. Comparison of two EpCAM-based methods for CTC detection and molecular characterization in advanced colorectal cancer. *Preprints*. Preprints.org. 2016, pp.2016110105.
- 36 **Scientific paper.** 2016. C8-T1 radiculopathy due to an intramural extra medullary metastasis of a pancreatic neuroendocrine tumor. *Pancreas*. Wolters Kluwer Health, Inc.. 45-5, pp.772-779.
- 37 **Scientific paper.** 2015. Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. *Pancreatology*. ELSEVIER. 15-4, pp.440-444.
- 38 **Scientific paper.** 2015. Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib. *Anticancer Drugs*. Wolters Kluwer Health Inc. 26-1, pp.112-116.
- 39 **Scientific paper.** 2015. Gastric and esophageal metastases in renal cell carcinoma: systematic review and management options. *International Cancer Conference Journal*. Springer. 4-1, pp.1-12.
- 40 **Scientific paper.** 2014. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. *Journal of Cancer Research and Treatment*. Wolters Kluwer. 10-4, pp.967-972.
- 41 **Scientific paper.** 2011. Varón joven con tromboembolismo pulmonar y niveles elevados de factor VIII. *Angiología*. ELSEVIER. 64-1, pp.63-65.
- 42 **Scientific paper.** FOLFIRI REGIMEN AS SECOND-LINE TREATMENT OF METASTATIC GASTRIC CANCER: A RETROSPECTIVE ANALYSIS OF EFFICACY, SAFETY AND PROGNOSTIC FACTORS. *European Journal of Oncology*. Mattioli. 20-1.

- 43 **Scientific paper.** Miguel Sotelo; José Ángel García-Sáenz; Luis Manso; et al; Eduardo Díaz-Rubio. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. *J Cancer Res Ther.* 2014 Oct-Dec;10(4):967-72. 10-4, pp.967-972.
- 44 **Book chapter.** 2021. Capítulo 8: Cáncer de Cabeza y Cuello. INMUNOONCOMECUM 2021. PERMANYER. pp.101-119.
- 45 **Book chapter.** 2019. Capítulo 8: Cáncer de cabeza y cuello. INMUNOONCOMECUM 2019. PERMANYER. pp.101-114.
- 46 **Book chapter.** 2018. Inmunoterapia en el cáncer de cabeza y cuello. Inmunoterapia para oncólogos. Aran Ediciones.
- 47 **Book chapter.** 2015. Prevention of Cardiotoxicity: New Strategies in the Management of Cancer Therapeutics. *Cardio Oncology.* CTO Editorial. Capítulo 19.
- 48 **Scientific edition.** Santiago Cabezas-Camarero; Almudena Alonso-Ovies; Salomé Merino-Menéndez; María Nieves Cabrera-Martín; José Carlos Plaza-Hernández; Pedro Pérez-Segura. 2021. Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer. *Oral Oncology.* 123-105589, pp.1-4.
- 49 **Review.** Santiago Cabezas Camarero. 2021. Opciones terapéuticas en gliomas de alto grado del anciano. *Revisiones en Cáncer.* ARAN EDICIONES. 35-4, pp.192-200.
- 50 **Bibliographic review.** Santiago Cabezas Camarero; Pedro Perez Segura. 2016. Tratamiento de la enfermedad recurrente irresecable o metastásica. *Revisiones en cáncer.* Arán Ediciones SL. 30-4.
- 51 **Bibliographic review.** Santiago Cabezas Camarero; Ana María Luna Barrera; Pedro Pérez Segura. 2016. Systemic Treatment of Low-Grade Gliomas. *Cancer & Chemotherapy Reviews.* Permanyer. 11-2.
- 52 **Módulo III Curso Online Inmunología e Inmunoterapia en Cáncer de Cabeza y Cuello.** 2018. Inmunología e Inmunoterapia en el Cáncer de Cabeza Y Cuello. Módulo III Curso Online Inmunología e Inmunoterapia en Cáncer de Cabeza y Cuello. HealthKeyCenter.

C.3. Research projects and contracts

- 1 **Project.** COMPARISON OF RAS STATUS IN CIRCULATING TUMOR CELLS ENTRE EL ESTATUS DE RAS IN CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA IN RAS WILD-TYPE METASTATIC COLORECTAL CANCER USING ISOFLUX AND BEAMING. Instituto de Salud Carlos III. Eduardo Díaz-Rubio García. (Hospital Clínico San Carlos). 01/01/2017-31/12/2019. 84.700 €.
- 2 **Project.** IDENTIFICATION OF PREDICTIVE MOLECULAR MAKERS OF THE DEVELOPMENT OF CANCER IN PREMALIGNANT LESIONS OF THE LARYNX AND CONTRIBUTION TO THE PROCESS OF CARCINOGENESIS IN HEAD AND NECK CANCER. Asociación Española Contra el Cáncer. Santiago Cabezas Camarero. (Hospital Clínico San Carlos). 01/03/2016-01/03/2019. 70.160 €.
- 3 **Project.** STUDY OF IDH MUTATIONAL STATUS AND EXPRESSION OF IMMUNOREGULATORY FACTORS IN CIRCULATING TUMOR DNA WITH CORRELATION TO THE PRIMARY TUMOR IN PATIENTS WITH GLIOMA. Grupo español de investigación en neurooncología (GEINO). Santiago Cabezas Camarero. (Hospital Clínico San Carlos). 25/11/2016-25/11/2018. 15.000 €.